Beyond Traditional Tech: What Really Drives Valuation in Digital Health

Digital health is in a period of rapid and meaningful transformation. Advances in artificial intelligence, expansion of telehealth and a system-wide shift toward data-driven decision-making are reshaping how clinical care is delivered. But unlike traditional tech, where scale is driven primarily by user acquisition and market momentum, digital health must operate within the constraints of regulation, clinical rigor, privacy requirements and payor economics. Companies must demonstrate evidence, compliance maturity and real-world integration readiness before they can earn trust.

Valuation functions as an integrated assessment of the regulatory defensibility, clinical credibility and operational maturity of a value proposition in the digital health space. This is where digital health organizations can rely on advisory services to help navigate valuation, regulatory alignment and operational enablement.

How Digital Health Differs from Traditional Tech

Regulatory Burden: Digital health must deal with overlapping federal and state regulations, data privacy and security requirements, and clinical liabilities that SaaS companies simply do not encounter. Growth rests not on rapid market adoption, but on progressing through a series of compliance milestones.
Scalability Constraints: Healthcare’s fragmented infrastructure creates friction that limits the speed to scale. Companies that can demonstrate scalability through entrenchment command meaningfully higher valuations.
Early-Stage Cash Flow Drag: Heavy regulatory preparation (e.g., clinical studies, audits, documentation) introduces material expense early in the business lifecycle.
Compliance Maturity as a Value Signal: Regulatory transparency materially lowers the overall risk profile. Clearances, certifications and validated clinical outcomes signal operational readiness and long-term viability.
Operational Complexity: Digital health is subject to various operational hurdles that directly affect cost structure, scalability and long-term financial performance.
Labor-Driven Margin Constraints: Clinical operations require licensed or credentialed staff, which introduces a labor intensity that constrains margin expansion.
Integration Drag: Fragmented governance frameworks and interoperability challenges create frictions that increase implementation costs and elongate sales cycles.
Workflow-Dependent Adoption: A value proposition in digital health can only succeed if it aligns seamlessly with clinical workflows. Any proposition that can reduce administrative burdens, streamline care coordination, or alleviate burnout is far better positioned for adoption and retention than solutions that fail to embed into workflows.
Clinical Validation: While traditional tech typically relies on usage metrics or adoption curves to demonstrate value, digital health companies are required to demonstrate clinical efficacy and measurable outcomes.
Competitive Edge: Generating credible clinical evidence (e.g., peer-reviewed studies, real-world data, validated ROI analyses) requires time, specialized expertise and substantial investment. Once secured, this evidence is difficult for competitors to replicate.
Commercial Acceleration: Clinically validated solutions experience stronger adoption, higher renewal rates and greater pricing power.
Validation-Driven Risk Profiles: Verified clinical outcomes reduce the probability of regulatory setbacks and strengthen payor negotiations. This reduction in perceived risk lowers discount rates in valuation models and increases confidence in projected cash flows.
Pathways to Revenue: While traditional tech typically relies on straightforward revenue models (e.g., subscription revenue for a software business), digital health companies depend on payor coverage decisions, CPT codes, value-based arrangements and employer benefits integration.
Reimbursement-Tied Revenue Predictability: Established reimbursement pathways (e.g., approved CPT codes, contracts with payors) translate to more predictable revenue streams and lower adoption risk.
Slow, Multi-Stakeholder Sales Cycles: Payor and health system procurement processes often take 12–24 months and require pilot phases, integration milestones or outcomes validation.
Distribution and Access Friction: Market access in healthcare is shaped by fragmented delivery systems, varying state regulations and the influence of multiple gatekeepers.
Intangible Assets: Because companies in this sector are typically light on tangible assets and face long commercialization timelines, investors rely heavily on non-physical assets to assess future performance. As such, intangible assets are the biggest drivers of enterprise value.
Revenue Visibility: Contract-based intangibles (e.g., payor agreements, provider partnerships) serve to stabilize future cash flows. These long-term relationships improve revenue predictability and reduce churn risk.
Defensibility and High Costs to Recreate: Certain intangibles in digital health (e.g., proprietary datasets, clinically informed algorithms) can take years of iteration and governance to build. Because these assets create meaningful competitive defensibility through high recreation costs, they strengthen cost-based valuation methodologies, reduce perceived competitive risk and justify higher valuation multiples.
Reflection of Compliance Maturity: Regulatory assets (e.g., FDA clearances, HITRUST certifications) act as intangible indicators of safety and readiness.

The next step is not just better data, but how that data shapes delivery. Part 4 explores how PMOs are moving toward hybrid methodologies and matching the right approach to each project.

How Valuation Informs Market and Capital Decision-Making

In digital health, valuation is a strategic instrument that directly shapes the ability to raise capital, access markets, build partnerships and attract the talent required to scale.

Governance and Investor Alignment: A defensible valuation provides a shared foundation for leadership teams and investors and helps unify decision-making. By translating clinical evidence, payor progress and operational readiness into economic terms, valuation helps clarify priorities and eliminate guesswork.
Capital Allocation and Investment Prioritization: Because digital health companies must sequence development around regulatory timelines and enterprise sales cycles, valuation helps identify which investments will meaningfully enhance long-term value. This disciplined lens also supports smarter decisions when evaluating whether to double down, pause or pivot.
Negotiating Leverage: Valuation grounded in measurable outcomes strengthens a company’s negotiating position. When a digital health solution can quantify the financial impact of improved outcomes or operational efficiency, pricing discussions shift from anecdotal to actuarial.
Access to Financing: Lenders and potential acquirers are increasingly evaluating intangible assets as part of their underwriting or diligence process. A strong, well-documented valuation acts as reassurance and signals operational maturity.
Partnership and M&A Pathways: Valuation acts as a visible signal of legitimacy and long-term viability within the crowded digital health ecosystem. Buyers and stakeholders favor well-capitalized partners capable of supporting multi-year engagements.
Talent Acquisition and Internal Leverage: Valuation plays a central role in attracting mission-critical talent by directly shaping the strike price of stock options and the perceived upside of joining the company.
FMV Compliance: A growing number of digital health companies operate within MSO-PC structures, whereby a management services organization (“MSO”) provides non-clinical services while the physician-owned professional corporation (PC) provides clinical services. For companies operating with these structures, valuation plays an essential compliance role by demonstrating that management fees reflect fair market value and reinforcing internal discipline.

What Comes Next: Advisory Led Valuation

Digital health’s path to scale is shaped by regulation, clinical rigor, privacy requirements and payor economics. Valuation serves as an integrated assessment of regulatory defensibility, clinical credibility and operational readiness. Navigating these interdependencies requires experienced advisory support that can align valuation with regulatory strategy and execution. For digital health organizations, the right advisors are essential to translating complexity into defensible, sustainable value.